Since a previous study showed that PBMCs from patients with APLAID were found to secrete IL-1β in response to LPS priming (13), IL-1 inhibitors may be considered to treat APLAID. This evidence concerns the gene IL1B and autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation.